Various compounds targeted at the NCp7 zinc fingers have been developed, but only one, HPH116 (cGMP micronized azodicarbonamide), has entered clinical trials so far.
2008
HPH116 is safe
for HIV+ individuals up
to 1.2g bid
HPH116
Food Drug Interaction
is achieved.
H-Phar foreseens a pilot
therapeutic vaccine clinical trial
in Q4 2009
